(Q37003208)

17 August 2017

1 reference

title

Subclinical damage to the nigrostriatal dopamine system by MPTP as a model of preclinical Parkinson's disease: a review (English)

1 reference

17 August 2017

Subclinical damage to the nigrostriatal dopamine system by MPTP as a model of preclinical Parkinson's disease: A review (English)

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05017.X

29 November 2022

0 references

1 reference

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05017.X

29 November 2022

author name string

R. S. Burns

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1801534

29 November 2022

language of work or name

1 reference

1 January 1991

1 reference

full work available at URL

17 August 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1600-0404.1991.tb05017.x

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05017.X

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0404.1991.tb05017.x/fullpdf

29 November 2022

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05017.X

Acta neurologica Scandinavica. Supplementum

29 November 2022

published in

1 reference

17 August 2017

136

1 reference

17 August 2017

29-36

1 reference

Deficits in operant behaviour in monkeys treated with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

17 August 2017

1

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05017.X

Asymptomatic striatal dopamine depletion: PET scans in unilateral MPTP monkeys.

29 November 2022

2

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05017.X

MPTP, impairment of motor performance and amine accumulation in Macaca fascicularis

29 November 2022

3

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05017.X

Amine accumulation, catecholamine depletion and motor impairment in Macaca fasicularis and the C-57 black mouse after MPTP administration.

29 November 2022

4

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05017.X

Differential responsiveness to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in sub-regions of the primate substantia nigra and striatum

29 November 2022

5

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05017.X

Cognitive and motor deficits in the acquisition of an object retrieval/detour task in MPTP-treated monkeys

29 November 2022

6

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05017.X

Cognitive and motor deficits in the performance of an object retrieval task with a barrier-detour in monkeys (Cercopithecus aethiops sabaeus) treated with MPTP: long-term performance and effect of transparency of the barrier.

29 November 2022

7

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05017.X

Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys.

29 November 2022

9

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05017.X

Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF.

29 November 2022

10

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05017.X

MPTP reduces dopamine and norepinephrine concentrations in the supplementary motor area and cingulate cortex of the primate

29 November 2022

11

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05017.X

MPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys.

29 November 2022

12

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05017.X

Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates: biochemical changes in striatal regions

29 November 2022

13

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05017.X

6-18F-L-dopa imaging of the dopamine neostriatal system in normal and clinically normal MPTP-treated rhesus monkeys

29 November 2022

14

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05017.X

Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin

29 November 2022

15

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05017.X

Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease

29 November 2022

16

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05017.X

Intellectual changes in patients with MPTP-induced parkinsonism

29 November 2022

18

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05017.X

Cognitive change following MPTP exposure.

29 November 2022

19

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05017.X

MPTP-induced parkinsonism

29 November 2022

20

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05017.X

The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

29 November 2022

21

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05017.X

29 November 2022

Identifiers

0 references

1 reference